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Reactive oxygen species (ROS) have been implemented in the etiology of pulmonary fibrosis (PF) in
systemic sclerosis. In the bleomycin model, we evaluated the role of acquired mutations in mitochondrial
DNA (mtDNA) and respiratory chain defects as a trigger of ROS formation and fibrogenesis. Adult male
Wistar rats received a single intratracheal instillation of bleomycin and their lungs were examined at
different time points. Ashcroft scores, collagen and TGFb1 levels documented a delayed onset of PF by day
14. In contrast, increased malon dialdehyde as a marker of ROS formation was detectable as early as
24 hours after bleomycin instillation and continued to increase. At day 7, lung tissue acquired significant
amounts of mtDNA deletions, translating into a significant dysfunction of mtDNA-encoded, but not
nucleus-encoded respiratory chain subunits. mtDNA deletions and markers of mtDNA-encoded
respiratory chain dysfunction significantly correlated with pulmonary TGFb1 concentrations and predicted
PF in a multivariate model.
S
cleroderma (also called systemic sclerosis, SSc) is a disease in which interstitial lung involvement represents
the most frequent cause of death1. It is believed that pulmonary fibrosis (PF) results from a sequential
‘multi-hit’ lung injury, after which incomplete alveolar epithelial repair processes foster the release of
profibrotic mediators such as transforming growth factor (TGF) b, progressive accumulation of excess extra-
cellular matrix, collagen, and scar formation, ultimately leading to architectural distortion2,3. Despite some
evidence for an involvement of the immune system, the pulmonary collagen deposits are in clinical practice
rarely amenable to immunosuppressive therapy and many patients have remarkably little evidence of cellular
inflammation in the pulmonary parenchyma4,5.
The exact initial triggers of the lung injury are not known but several lines of evidence point towards an
important role of reactive oxygen species (ROS). ROSwere found at great abundance early in the disease process6,7
and were found to be constitutively produced by fibroblasts; conversely ROS enhance fibroblast proliferation and
collagen formation8. Themechanism that perpetuates the production of superoxide and hydrogen peroxide in SSc
fibroblasts is not understood but it is intracellular and independent of cytokines8. ROS also activate latent TGFb1,
which in turn fosters the production of more ROS9–11. This intrinsic TGFb1 cycle also promotes the epithelial
mesenchymal transition (EMT), a process in which pulmonary epithelial cells transform to fibroblasts and
myofibroblasts10,12,13. The importance of ROS in PF is also highlighted by the fact that N-acetylcysteine, a
glutathione precursor that inhibits that myofibroblast formation14, attenuated PF in an animal model15 and in
combination with other drugs - the decline of lung function in a randomized trial of patients with idiopathic PF16.
Up to now. the exact role of oxidant stress in the pathogenesis of human PF remains unclear, and the use of anti-
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oxidants controversial. An ongoing clinical comparison of N-acet-
ylcysteine alone andmatching placebowill help to shedmore light on
the therapeutic role of this antioxidant in patients with idiopathic
PF17.
Mitochondria may be involved in the pathogenesis of PF because
on the one hand, they are the main cellular producers of ROS and on
the other hand are themselves subject to oxidative injury of their
lipids, protein structures and genome (e.g. mitochondrial DNA,
mtDNA). In this study, we investigate the specific hypothesis that
mutations in mtDNA accumulate with time during the progression
of PF and contribute to, or may even be an important driver of ROS
production and subsequent fibrosis. Our hypothesis hinges on the
fact that unopposed mtDNAmutagenesis interferes with mitochon-
drial transcription and respiratory chain protein synthesis, a process
which augments the liberation of ROS, which then either attack the
respiratory chain itself, or in turn damagemtDNA18. ROSmay there-
fore close vicious circles of interconnected mtDNA and respiratory
chain insults. Such vicious circlesmay continue to operate even in the
absence of the inciting event and since mitochondrial ROS are also
potent activators of TGFb110,16 then account for the relentless pro-
gression of PF (figure 1)8.
In this study, we investigated the hypothesis of somatically
acquired lesions in mitochondria as possible perpetuators of the
relentless disease process by investigating mtDNA mutations and
their association with interstitial lung disease in a bleomycin model
of PF19. We chose the bleomycin model because (i) bleomycin
induces ROS, (ii) high doses of bleomycin frequently induce PF in
humans and (iii) the development of SSc-like skin fibrosis has been
observed in patients treated with bleomycin20.
Results
Delayed onset of bleomycin lung injury. The pulmonary collagen
content measured by means of the hydroxyproline assay increased
with time. From amean of 113 mg/mgwet tissue (SD 74) in the group
not treated with bleomycin (control rats), the mean pulmonary
hydroxyproline content increased by 154% after 48 hours (p 5
0.08.), 169% after 7 days (p 5 0.016), and 167% after 14 days (p 5
0.01). Similarly, in the control animals, the median Ashcroft score
was 1.2 (interquartile range (IQR) 1.0, 1.6). At 24 hours and
48 hours after bleomycin instillation, the Ashcroft score remained
unchanged with median scores of 1.1 and 1.2, respectively. The
Ashcroft score increased 7 days after bleomycin instillation with a
median Ashcroft score of 1.8, (IQR 1.4, 2.2, p 5 0.053, Table 1) but
only at the 14 day time point, the Ashcroft score differed significantly
from control values (median 2.5, IQR 2.0, 3.1), p 5 0.014, Table 1).
As expected, the Ashcroft score and the results from the
hydroxyproline assay correlated (r 5 0.41, p 5 0.004).
Taken together, the results demonstrate that the development of
PF was time dependent and significantly established not before one
to two weeks after bleomycin instillation.
a-SMA immunoreactivity was detected in normal lungs, only in
the trachea and smooth muscle cells of the pulmonary blood vessels
and no significant changes were observed 24 hours post bleomycin
instillation. While a few immunoreactive cells were observed at
48 hours, larger areas of a-SMA immunoreactivity were observed
in the thickened interstitial space after 7 days, increasing in number
and size at day 14 after bleomycin injury (Figure 2). These data
confirm the presence of myofibroblasts in the fibrotic scar.
Delayed increase of pulmonary TGFb1 formation. Similar to the
onset of PF, the levels of pulmonary TGFb1 as a key profibrotic
cytokine showed an increase with time (Table1). The median
pulmonary TGFb1 content increased from baseline (2.27 ng/ml,
IQR 1.76, 2.48) but was significantly different from control lungs
only at day 14 (2.86 ng/ml (IQR 2.76, 2.99, p , 0.001). TGFb1
levels significantly correlated with the increased collagen content (r
5 0.44, p 5 0.002) and coincided with the deteriorating Ashcroft
score.
ROS are formed early and increase with time. MDA levels as an
indirect indicator of the formation of ROS were elevated in the lung
early after bleomycin administration (Table 1). Even after 24 hours,
the median MDA levels were augmented (p 5 0.02); MDA then
continued to increase progressively and the highest MDA levels
were measured 14 days after bleomycin instillation (p , 0.001,
Table 1). MDA levels were also loosely, but significantly correlated
with the pulmonary collagen content (r 5 0.3, p 5 0.03) and with
TGFb1 concentrations (r 5 0.30, p 5 0.02).
Figure 1 | Simplified hypothesis of mitochondrial involvement in the
pathogenesis of bleomycin induced PF. Bleomycin induces ROS that are
perpetuated by positive feedback loops involving respiratory impairment
and mitochondrial mutagenesis. ROS, respiratory chain dysfunction, or a
combination of both, then induce TGFb1 and interstitial lung disease3,10.
Table 1 | Effects of bleomycin on lung mitochondria. * p , 0.001 vs. 0 hours; { p , 0.05 vs. 0 hours
Time after intratracheal bleomycin 0 hours 24 hours 48 hours 7days 14 days
Number of rats examined 10 10 9 10 10
Ashcroft score, median (IQR) 1.2 (1.0, 1.6) 1.1 (1.0, 1.2) 1.2 (1.0, 1.7) 1.8 (1.4, 2.2) 2.5 (2.0, 3.1){
Collagen (mg/mg wet tissue), mean (SD) 113 (74) 30 (9){ 174 (70) 192 (58){ 189 (37){
TGFb1 (ng/ml), median (IQR) 2.27 (1.76, 2.48) 2.09 (1.97, 2.24) 2.60 (2.07, 2.95) 2.41 (2.19, 2.75) 2.86 (2.76, 2.99)*
Malon dialdehyde (mmol/g lung), median (IQR) 29 (21, 43) 64 (53, 70){ 89 (84, 98){ 102 (91, 146)* 125 (106, 221)*
Total mtDNA copy number/cell, mean (SD)
((mean(m(mean copies/cell)
59 (10) 65 (21) 58 (11) 64 (20) 50 (10){
Common deletion (% of total mtDNA), median (IQR) 0 (0, 17) 0 (0, 7) 0 (0, 21) 30 (20, 44){ 47 (42, 54)*
COX-activity (mmoles min21 g protein21), mean (SD) 1.7 (1.8) 0.8 (0.4) 2.0 (2.3) 0.9 (1.0) 0.3 (0.2)*
COX/SDH-ratio, mean (SD) 1.8 (1.9) 1.5 (1.9) 1.0 (1.0) 0.6 (0.8){ 0.1 (0.1)*
COXI/COXIV-ratio (% of control), mean (SD) 100 (20) 132 (28){ 63 (16)* 76 (30){ 59 (11)*
COXIV/GAPDH-ratio (% of control), mean (SD) 100 (22) 80 (18) 100 (20) 101 (23) 97 (6)
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These data demonstrate that ROS formation occurs early after the
instillation of bleomycin, continues to increase in the absence of
further bleomycin applications, and precedes the development of PF.
mtDNA mutagenesis coincides with the onset of PF. The mean
pulmonary copy numbers of total mtDNA remained unchanged
compared to controls at 24 hour, 48 hour and 7 day time points
(Table 1). Fourteen days after the bleomycin instillation however,
the mtDNA copy numbers were significantly reduced compared to
controls (mean wild type mtDNA levels 84% of control values, p 5
0.046).
The ‘common’ mtDNA deletion was only detected at low levels in
control lungs and at the early time points after bleomycin exposure
(Table 1). Six control animals, eight animals at the 24 hour time
point and six animals at the 48 hour time point did not have any
detectable deletion. In contrast, the ‘common’ deletion was detected
in all rats after 7 and 14 days, when also high proportions of mtDNA
molecules were detected (median percentage of deleted among total
mtDNA molecules 30%, p5 0.006 and 47%, p, 0.001, respectively
vs. 0% in controls).
Among all rat lungs, the proportions of deletedmtDNAmolecules
positively correlated with the degree of PF as assessed by Ashcroft
score (r5 0.48, p, 0.001, figure 3), pulmonary collagen content (r5
0.26, p , 0.001), and TGFb1 levels (r 5 0.57, p , 0.001, figure 3).
These data indicate that the accumulation of significant amounts of
mtDNA mutations coincides with the onset of PF.
Delayed onset of mtDNA-encoded respiratory chain dysfunction.
Wemeasured the activity of COX, a mitochondrial respiratory chain
enzyme whose subunits are encoded in part by mtDNA and in part
by nDNA. Fourteen days after bleomycin injury, the ratio of COX
activity/wet tissue was significantly reduced (p , 0.02) with only
17.6% of control activity remaining (Table 1).
We then normalized COX activity for the activity of SDH, a res-
piratory chain enzyme that is exclusively encoded by nDNA. In the
lungs the resulting mean COX/SDH-ratio was 1.8 in control rats and
decreased progressively to 83%, 57%, 33% and 6%, at 24 hours,
48 hours, 7 days and 14 days (Table 1). This progressive loss of
mtDNA-encoded respiratory chain activity also highly correlated
with the frequency of the mtDNA common deletion (r 5 20.37,
p 5 0.007) and with TGFb1 levels r 5 0.57, p , 0.001). COX
histochemistry confirmed the downregulation of COX-activity,
although a particular cell type accounting for this effect could not
be observed (Figure 2).
We then analyzed the subunit composition of COX by means of
Western Blots and normalized the expression of the mtDNA
encoded COX subunit I for that of the simultaneously probed
nDNA-encoded COX subunit IV. The mean COXI/COXIV-ratio
was increased in the rats at 24 hours (132% compared to controls),
but was substantially reduced at 48 hours, 7 days and 14 days after
bleomycin exposure (mean COXI/COXIV-ratio 63%, 76% and 60%
of control values (Table 1). Furthermore, the COXI/COXIV-ratio
was negatively correlated with the collagen content in the lungs
(r 5 20.57, p , 0.001), the pulmonary TGFb1 content (r 5 20.58,
p , 0.001), the pulmonary concentrations of MDA (r 5 20.30, p 5
0.035), and the frequency of mtDNA deletions (r520.36, p5 0.01).
By means of Western blot, we lastly quantified the presence of the
COXIV subunit by normalizing the COXIV signal to that of the
simultaneously probed GAPDH protein in lung tissue. The resulting
COXIV/GAPDH-ratio is an indicator of the expression of nDNA-
encoded respiratory chain components but did not statistically differ
between time points and did not correlate with both markers of PF
and TGFb1 concentrations in the lung.
These results indicate that the reduced mitochondrial respiratory
chain activity is highly correlated with markers of PF and can be
attributed to a defect in the mtDNA-encoded, but not to nDNA-
encoded COX subunits whereas the expression of nDNA-encoded
respiratory chain components is entirely preserved.
Electron microscopy of lung tissue at day 14 (Figure 2) revealed a
pronounced enlargement and a disrupted architecture of pulmonary
mitochondria, similar to that seen in other mitochondrial disorders
[28]. Less pronounced, but similar ultrastructural abnormalities of
the mitochondria were also seen at day 7, but not at earlier time
points.
Multivariate analysis of parameters associated with PF. Finally, we
identified independent predictors of Ashcroft scores, pulmonary
hydroxyproline and TGFb1 content in a multivariate median
regression analysis (Table 2). This analysis confirms acquired
mtDNA deletions and markers of respiratory chain dysfunction,
underscoring the association of mtDNA mutagenesis and mtDNA-
encoded respiratory defect with the delayed acquisition of PF.
Figure 2 | Effects of bleomycin on lung histology. Representative electron
micrographs (A, B) demonstrate mitochondrial enlargement, disrupted
crystal architecture and intracytoplasmic vacuoles in an alveolar epithelial
cell at day 14. Panels C and D demonstrate depressed COX activity in
pulmonary tissue at day 14 (brown stain in COX/SDHhistochemistry) and
an upregulation of SDH activity (blue stain) not visible at day 0 (insert in
panel D). Panels E and F show the expression of aSMA. In normal lung,
brown staining was only observed in the smooth muscle around the
airways (E); a representative slide of lung tissue 14 days after bleomycin
however documents excess aSMA expression in the thickened interstitial
space (F). Magnification bars: 4 mm (A,B), 40 mm (C,D, insert D); 100 mm
(E,F).
www.nature.com/scientificreports
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Figure 3 | Correlations between PF, pulmonary TGFb1 content, mitochondrial mutagenesis and mitochondrial function.
www.nature.com/scientificreports
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Discussion
The aim of this study was to investigate the role of somatically
acquired mitochondrial dysfunction in the irreversible perpetuation
of PF in a rat lung fibrosis model. We demonstrate that a single
instillation of bleomycin induces ROS formation with early func-
tional and genetic mitochondrial lesions and that these mitochon-
drial defects are perpetuated and augmented with time in the absence
of additional bleomycin dosing. It is known that quantitative and
qualitative mtDNA-defects must exceed a threshold in order to
achieve pathogenic relevance21, possibly accounting for the onset of
fibrotic activity at later stages.
Importantly, our data indicate that the respiratory impairment is
associated with selective impairment of mitochondrial, but not nuc-
lear encoded respiratory chain subunits. ROS also impair the func-
tion of polymerase-gamma, the enzyme responsible for mtDNA
replication. This fact may account at least in part for the decrease
in total mtDNA levels observed at day 14 and contribute to the
functional defect in the expression of mtDNA encoded respiratory
chain subunits.
An aberrant response to recurrent insults is now accepted as an
important mechanism in the etiology of PF2,3. There is ample evid-
ence suggesting that ROS are generated in the pulmonary par-
enchyma and play a vital role in fibrotic process6,7,9. Bleomycin
releases large amounts of ROS22–25 which are important in the onset
of PF in this model, as highlighted by the fact that the absence of ROS
is protective26.
In the current study we demonstrate that marked mitochondrial
impairment is a likely significant source of ROS and its profibrotic
mechanism. Furthermore, interconnected and via ROS-formation
self-perpetuating and self-augmenting mtDNA and respiratory
chain insults could explain the relentless progression and delayed
onset of PF8. It is however still not fully understood, if mitochondrial
damage also promotes PF through mechanisms other than ROS-
formation and subsequent activation of TGFb110,27, for example by
directly triggering apoptotic pathways in the lung parenchyma28.
The mitochondrial theory of ageing associates oxidative stress
with mitochondrial mutagenesis and respiratory dysfunction of
organs at senescence29,30. Our data therefore provide an explanation
for the so far elusive link between ageing as perhaps the strongest
non-environmental risk factor for interstitial lung involvement and
the onset of PF in non SSc patients3,31. Such mitochondrial impair-
ment has been demonstrated in models of liver fibrosis and there is
growing interest in the potential role of acquired mtDNAmutations
in other late-onset diseases30.
Mitochondria participate in cold-induced vasospasm (Raynaud’s
phenomenon), a symptom that is present in virtually every SSc
patient32,33. In Raynaud’s phenomenon, mitochondria generate
ROS in vascular smooth muscle cells which then augment vasocon-
striction by mobilizing adrenoceptors to the cell surface via the
RhoA/Rho kinase (ROCK) pathway32–34. It is therefore interesting
to speculate if the pathogenetic mechanisms that operate in SSc are
associated with mitochondrial damage in other organ systems.
We have to acknowledge, that our results, although compelling, do
not provide causal proof of the pathogenetic role of mitochondrial
dysfunction in lung injury. Recent data however found a suppressed
synthesis of alveolar ATP and mitochondrial dysfunction in an in
vivo model of acute lung injury and even more importantly, it was
demonstrated that the experimental normalization of mitochondrial
bioenergetics was protective35.
We do not know which cell types account for our findings.
Fibroblasts are a possible candidate, because when explanted from
fibrotic lungs after bleomycin treatment these cell types retain their
profibrotic phenotype in culture36, in support of an intracellular
defect which is possibly fixed in the mitochondrial genome. In our
study, we analyzed the respiratory chain activity by means of histo-
chemistry but were not able to demonstrate the specific involvement
of a particular cell type. This finding was strengthened by electron
microscopy which revealed ultrastructural damage of mitochondria
in a variety of pulmonary cells, including alveolar epithelial cells.
Alveolar epithelial cells may also provide a source of ROS, as they
have been shown to be subject to mtDNA injury and consecutive
apoptosis37. Failure of alveolar epithelial cells to reepithealize in res-
ponse to injury is an importantmechanism in the pathogenesis of PF.
It is therefore likely, that several cell types account for our findings.
Current studies from our group now determine the presence and
functional relevance of mtDNA mutagenesis in lung biopsies from
patients with PF. Additional in vitro studies using fibroblasts devoid
of any mtDNA38 will help to elucidate the effect of mitochondrial
lesions on the response of lung fibroblasts to profibrotic stimuli. Our
findingsmay also help in the rational development of protective ROS
scavengers.
Conclusions
Our data suggest that mtDNA alterations and respiratory chain
defects, initiated during acute bleomycin exposure, and gradually
accumulating over time could represent an important factor in the
delayed onset of PF and in the perpetuation of ROS-mediated lung
injury.
Methods
Animals. Fifty adult male Wistar rats (220–240 g) were obtained from the animal
care facility in Bern, Switzerland. Experiments were performed in accordance to the
standards of the European Convention of Animal Care. The study protocol was
approved by the University of Bern Animal Study Committee.
Instillation of bleomycin. At day one of the protocol, rats were anesthetized by
inhalation of 4% isoflurane, intubated with a 14 gauge catheter (Insyte, Madrid,
Spain) and instilled intratracheally with bleomycin (1.28 U/rat) to both lungs. The
dosage of bleomycin was based on preliminary experiments showing induction of PF
with lowest mortality39. Animals were sacrificed in groups of ten 24 hours, 48 hours,
7 days, or 14 days after intratracheal bleomycin instillation. Lung aliquots were either
fixed in formalin or snap frozen for further analysis. Ten rats with no bleomycin
instillation served as controls. One rat in the 48 hour group was found dead 24 hours
after bleomycin instillation; therefore the 48 hour group had 9 animals available for
the analysis, whereas all other groups had 10 rats each.
Histology and Ashcroft scoring. The extent of PF was evaluated with the Ashcroft
score on formalin-fixed sections after haematoxylin and eosin staining of the mid
apical regions of the left and themiddle lobes of the right lungs40. The pathologist was
blinded to the group status of the specimen. Five microscopic fields were randomly
chosen and a score ranging from 0 (normal) to 8 (total fibrosis) was given to each field.
For each animal the mean score of all fields was calculated.
Hydroxyproline Assay. Lung collagen content was quantified by means of the
hydroxyproline assay as described39. Frozen middle regions of both lungs where
Table 2 | Acquired mtDNA mutations and respiratory chain dys-
function as independent predictors of Ashcroft scores, pulmonary
collagen deposition (hydroxyproline), and the proinflammatory
cytokine TGFb1. Significant p-values were calculated in a multi-
variate median regression analysis; non-significant variables are
presented as empty cells
Variable Ashcroft score
Hydroxyproline
concentration
TGFb1
concentration
Total mtDNA copy
numbers/lung cell
Common mtDNA
deletion (% of total
mtDNA)
0.004 0.02 0.003
Malon dialdehyde
concentration
COX-activity 0.01 0.005
COX/SDH-ratio
COXI/COXIV-ratio 0.03 ,0.001
www.nature.com/scientificreports
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weighted and homogenized. The homogenate was treated with 10% trichloroacetic
acid, hydrolyzed with 6 MHCl (18 hours, 110uC) and adjusted to pH 7.0 withNaOH.
Oxidation was initiated by incubation with 1 ml of chloramine T-reagent (20
minutes, room temperature) and stopped by addition of 1 ml of 3.15 MHClO4. After
incubation with Ehrlich reagent (p-dimethylaminobenzaldehyde added to methyl
cellosolve) for 20 minutes at 55-65uC the absorbance of each sample was measured at
557 nm. A standard curve was generated using known concentrations of
hydroxyproline. All chemicals were obtained from Sigma Aldrich, USA.
Electronmicroscopy. The lungs of two randomly selected rats from each group were
examined by electron microscopy. Aliquots were post-fixed in OsO4 (1%),
dehydrated and embedded in Epon41. Ultra thin sections were stainedwith lead citrate
and uranyl acetate and viewed in a Zeiss electron microscope (EM 900) operated at
50 kV.
ROS formation. Malondialdehyde (MDA) is one of the end products of lipid
peroxidation and an indicator of ROS production and oxidative stress. MDA was
spectrophotometrically quantified in tissues with an assay for thiobarbituric acid
reactive material, as described elsewhere41.
Measurement of TGFb1 levels in lung homogenate. Lung protein was extracted
using a lysis buffer containing PBS, Nonidet P-40 (1%), EDTA (100 mM), and
pepstatin A (1 mg/ml) and TGFb1 levels measured using an ELISA kit (R&D Systems,
Abingdon, U.K)39.
Anti a-smoothmuscle actin immunohistochemistry. Formaline fixed sections were
deparaffinised in xylene series and rehydrated in decreasing ethanol series. Slides
were pre-treated by microwave in citrate buffer (100 mM, pH 7.0) for 10 minutes,
washed three times with Tris-buffered saline containing 0.1% tween and incubated
overnight at 4uC with an anti a-smooth muscle actin (a-SMA) antibody (15100,
Sigma Aldrich, USA). Antibody binding was detected as a brown stain by means of a
peroxidase system and 3,39-diaminobenzidine as a substrate (EnVision and System
HRP DAB, Dako USA).
MtDNA-content. Total DNA was extracted with the QIAamp DNA isolation kit
(Qiagen, Hilden, Germany). MtDNA and nDNA copy numbers were determined by
quantitative polymerase chain reaction (PCR) using LightCyclerH 480 Real-Time
PCR System (Roche, Mannheim, Germany) on a 384 well plate. 10 ml reactions
contained 5 ml of SYBR Green I Master mix (Roche, Mannheim, Germany), 10 ng
DNA template and 0.5 mM of each primer. The mtDNA was amplified between
nucleotide positions 2469 and 2542with the forward primer, 59-AATGGTTCGTTT
GTTCAACGATT-39 and the backward primer 59-AGAAACCGACCTGGATTG
CTC-39. For the detection of nuclear DNA (nDNA) we selected GAPDH between
nucleotide positions 494 and 671, using the forward primer 59-TGC ACC ACC AAC
TGC TTA G-39 and the backward primer 59-GGA TGC AGG GAT GAT GTT C-39.
Amplifications of mitochondrial and nuclear products were separately performed as
triplicates, with the following conditions: an pre-incubation at 95uC for 5 min, was
followed by 40 cycles of a 3 steps amplification (95uC, 10 sec; 50uC 10 sec; 72uC
15 sec) ending with a melting curve for PCR product identification (95uC, 5 sec;
65uC, 1 min). Absolute mtDNA and nDNA copy numbers were calculated using
serial dilutions of plasmids with known copy numbers. ThemtDNA copy number per
pulmonary cell was calculated as the number of mtDNA copies per two nuclear DNA
copies.
Detection and quantification of the common mtDNA-deletion. The mtDNA
sequence contains direct repeats between which base pairs may be deleted by slipped
mispairing during replication42,43. A 4977 base-pair deletion is the most frequent
somatically acquired deletion in humans and therefore also termed ‘‘common’’
deletion. We probed for the 4834 base pair rat homologue of the ‘‘common’’ deletion
by amplifying 100 ng of genomic DNA with the following extradeletional primers
F7825 (59-TTT CTT CCC AAA CCT TTC CT-39) and B13117 (59-AAG CCT GCT
AGG ATG CTT C-39) in a PCR reaction44. By choosing a short extension cycle (30
seconds), the deleted molecule was preferentially amplified as a 459 base-pair
product. This PCR product was confirmed by sequencing to represent the ‘‘common’’
4974 base pair mtDNA deletion in rats. The deletion was quantified by densitometry
on agarose gels (Quantum ST4v16.03, Vilber Lourmat, Marne-la-Vallee, France) and
calibrated with PCR products from templates with known amounts of deleted
mtDNA (from cybrids, homoplasmic for the ‘‘common’’ mtDNA-deletion41,45.
Activity of themitochondrial respiratory chain.The enzyme activity of cytochrome
c-oxidase (COX), a multisubunit respiratory chain complexes which is encoded by
nuclear DNA (nDNA) and mtDNA, and succinate dehydrogenase (SDH), which is
encoded entirely by nDNA, weremeasured by spectrophotometry in freshly prepared
lung extracts, as described46.
MtDNA-encoded respiratory chain protein. The subunit I of cytochrome c-oxidase
(COXI) is encoded by mtDNA, whereas the subunit IV of cytochrome c-oxidase
(COXIV) is encoded by nDNA. The blots were also probed with an antibody
(Fitzgerald Industries International Inc., Acton, USA) against glycerol aldehyde
phosphate dehydrogenase (GAPDH), an enzyme which is entirely encoded in the
nucleus. COXI was quantified by immunoblot densitometry (Quantum ST4v16.03,
Vilber Lourmat, Marne-la-Vallee, France) and normalized to the signal of a
simultaneously used antibody against COXIV46.
Statistics.Using Sigma Plot (vs. 12.3) statistical software, repeatedmeasures Analysis
of variance (ANOVA) tests were used for between-group comparison, followed by t
tests or Wilcoxon-tests s. Linear or non-linear correlations were calculated as
appropriate. P values , 0.05 were considered significant. Multivariate median
regression analysis was applied to identify factors independently associated with
pulmonary collagen content, Ashcroft score, and TGFb1 levels.
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